

1 **A novel indomethacin / methotrexate / MMP-9 siRNA *in situ* hydrogel with dual**
2 **effects of anti-inflammatory and reversing cartilage disruption for the**
3 **synergistical treatment of rheumatoid arthritis**

4 Na Yin ^a, Xinyi Tan ^a, Hongbing Liu ^a, Fengming He ^b, Ning Ding ^a, Jingxin Gou ^a, Tian Yin ^c,
5 Haibing He ^a, Yu Zhang ^{a,*}, Xing Tang ^a

6

7 ^a Department of Pharmaceutics, Shenyang Pharmaceutical University, Wen Hua Road No. 103,
8 Shenyang, China

9 ^b School of Pharmaceutical Sciences, Xiamen University, South Xiang-An Road, Xiamen, China

10 ^c School of Functional Food and Wine, Shenyang Pharmaceutical University, Wen Hua Road No.
11 103, Shenyang, China

12

13 ***Corresponding author:**

14 **Professor Yu Zhang**

15 Tel: +86 24 23986343; Fax: +86 24 23911736. E-mail address: pharmzy@163.com

16

17

18

19

20

21

22

23 1. Synthesis and characterization of disulfide-crosslinked polyethyleneimine (PEI-SS)

24 The thiolated PEI was synthesized in two steps (Fig. S1) following a modified method as
25 described in the literature¹. The pH of the 1.2k PEI solution (2 g) was adjusted to 7.2 with 0.5 N
26 hydrochloric acid, and the resultant solution was lyophilized. The lyophilized product was dissolved
27 in methanol (30 ml) and purged with nitrogen for 20 minutes. A 5-fold molar excess or a 10-fold
28 molar excess of propylene sulfide compared to PEI was slowly added dropwise, and stirred at 60°C
29 for 24h under a nitrogen atmosphere. The reaction solution was evaporated to dryness under reduced
30 pressure to yield a yellow viscous solid. The product was dissolved in a small amount of methanol,
31 followed by precipitation twice in cold diethyl ether. To synthesize PEI-SS, the thiolated PEI (0.5 g)
32 was dissolved in DMSO (50 mL) and stirred at room temperature for 48h. The reaction solution was
33 purified by dialysis (MWCO 3,500) and then lyophilized to obtain PEI-SS. The ¹H NMR spectra of
34 the PEI-SS was obtained using a Bruker Avance III HD NMR spectrometer at 400MHz. The
35 molecular weight and polydispersity index of the PEI-SS was confirmed using gel permeation
36 chromatography (GPC) (solvent: acetic acid and sodium acetate buffer; concentration: 0.5 mol/L;
37 instruments: Waters 1515 GPC).





Figure S1. Synthesis procedure of PEI-SS



40
41
42
43

Figure S2. Characterizations of PEI-SS

Table S1. Characterizations of PEI-SS

	Mw (Da)	Polydispersity
PEI-SS-5	10,524	1.0971
PEI-SS-10	11,545	1.0967

44 2. Characterization of D/siRNA-NGel

45 2.1 Determination of gelation temperature and time

46 The gelation temperature of the drug-loaded gel was determined by the tube inversion method².
47 Briefly, 1 mL of the test solution was placed in a 10 mL test tube which was placed in a constant
48 temperature water bath and gradually heated at 1°C intervals. The temperature was held for 5 minutes
49 after reaching the specified temperature. The test tube was tilted at regular time intervals, and the
50 temperature at which the test solution was converted to a gel and ceased to flow with no change in
51 meniscus upon tilting up to 90° was recorded. The gelation time of the drug-loaded hydrogel was
52 determined by the same method. The test tube containing the test solution was placed in a constant
53 temperature water bath at 37°C, and the final gelation time was recorded when the test solution ceased
54 to flow when tilting to 90°. The measurement was performed 3 times in parallel, and the mean value
55 ± SD was calculated.


56 2.2 Determination of viscosity of *in situ* gel

57 The viscosity of the different F127 and F68 based formulations was determined using a rotary
58 rheometer. Briefly, an appropriate amount of sample was dropped in the middle of the Pel plate and
59 scanned for viscosity, using a 2° cone angle measuring head with a diameter of 40 mm, a test
60 temperature of 25°C, and a shear rate of 0-120 s⁻¹.

$$\text{Viscosity (Pa.s)} = \frac{\text{Shear stress(Pa)}}{\text{Shear rate(1/s)}}$$

61
62 **Table S2.** Properties of different combination of pluronic 127 (F127) and pluronic 68 (F68) *in situ* hydrogel systems
63 and the effect of shear force on viscosity of F127/F68 based *in situ* hydrogel formulations. Results are expressed as
64 mean values ± SD, (n = 3).

Formulation code	F127 (%W/V)	F68 (%W/V)	Gelation temperature(°C)	Gelation time (s)	Viscosity (Pa.s)
Gel 1	28	12.5	35.5 ± 1.0	21.31 ± 4.48	0.5753
Gel 2	28	15	34.5 ± 0.5	20.43 ± 1.25	0.5401
Gel 3	27	10	33.0 ± 0.5	12.31 ± 2.50	0.3964
Gel 4	26	10	36.0 ± 1.0	37.56 ± 5.31	0.3536




65
66 **Figure S3.** Shear stress-shear rate curve for different hydrogel formulations.

67 3. TEM scan of release medium


68 The drug-loaded temperature-sensitive gel mixture solution was directly added to the release
69 vial without a dialysis bag, and then the release vial was placed in a 37°C constant temperature water
70 bath to cause gelation. The pH 7.4 PBS was then added to the release vial containing the temperature-
71 sensitive gel. The vials were carefully placed in a shaking bath with constant temperature (37°C) and
72 shaking (100 rpm). The medium was completely removed at predetermined time points and

73 replenished with fresh medium. The release medium removed at each time was examined by TEM to
74 observe whether the nanoparticles was present in the release medium.




75
76 **Figure S4.** Transmission electron microscope (TEM) scanning images of the D/siRNA-NGel release medium at
77 different time points. Scale bar, 200 nm.

78 4. Hydrogel biodistribution in inflamed joints



79
80 **Figure S5.** *Ex vivo* imaging of major organs at 24h after intra-articular injection.

81 5. TEM scan of D/siRNA-NGel



82
 83 **Figure S6.** The transmission electron microscopy image of D/siRNA-NGel after 100 times dilution. Micellar
 84 aggregates (inside the blue frames) and some larger particles (inside the red frames) were shown.

85 6. Stability of D/siRNA-NGel

86 **Table S3.** *In vitro* stability of D/siRNA-NGel at 4°C.

Time	2h	4h	8h	12h	24h	48h
Appearance	Light yellow, clear and transparent solution	Light yellow, clear and transparent solution	Light yellow, clear and transparent solution	Light yellow, clear and transparent solution	Light yellow, clear and transparent solution	Light yellow, clear and transparent solution
Gelation temperature	33.0°C	33.2°C	33.1°C	33.0°C	32.9°C	33.1°C

87

88 References

- 89 1. S. Son, K. Singha and W. J. Kim, *Biomaterials*, 2010, **31**, 6344-6354.
 90 2. Z. M. A. Fathalla, A. Vangala, M. Longman, K. A. Khaled, A. K. Hussein, O. H. El-Garhy and R. G. Alany,
 91 *European Journal of Pharmaceutics and Biopharmaceutics*, 2017, **114**, 119-134.

92